

Diese Meldung kann unter <http://www.presseportal.de/meldung/1651524/> abgerufen werden.



EANS-Adhoc: Ad Hoc Announcement pursuant to para 15 WpHG (German Securities Trading Act)

Epigenomics AG: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United States

20.07.2010 - 16:56 Uhr, Epigenomics AG

-----  
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro  
adhoc with the aim of a Europe-wide distribution. The issuer is solely  
responsible for the content of this announcement.  
-----

New Products/Molecular diagnostics

20.07.2010

Berlin and Seattle, July 20, 2010 - Epigenomics AG (ISIN: DE000A0BVT96) reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., today has announced the launched of a laboratory-developed test for the blood-based detection of colorectal cancer. The test is based on Epigenomics' proprietary Septin9 biomarker and DNA methylation technologies non-exclusively licensed to ARUP in August 2009.

According to ARUP the independently developed and validated Septin9 test identifies nine out of ten people with previously undetected colorectal cancer, including those with early stage disease. ARUP states that the test, which is now available to physicians and patients in the U.S., is not meant to replace colonoscopy but primarily aims at patients who cannot or will not undergo the established screening methods.

Founded in 1984, ARUP Laboratories is a national reference laboratory and an enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. Clients across the United States include university teaching hospitals, multihospital groups, major commercial laboratories, military and other government facilities, as well as major clinics.

The launch of ARUP's Septin9 test marks another important milestone in Epigenomics' dual business strategy of direct commercialization and non-exclusive licensing and partnering of its proprietary biomarkers and technologies for cancer molecular diagnostics. Multiple in vitro diagnostic and laboratory-developed blood tests for the early detection of colorectal cancer based on the Septin9 biomarker have been made available since October 2009 in Europe, Asia/Pacific and the U.S. by Epigenomics and its partners Abbott Molecular, Quest Diagnostics, and ARUP Laboratories. Furthermore, Canadian Warnex Laboratories is working on a laboratory-developed test for Septin9 that is expected to be launched later this year.

End of Ad hoc

Please find the original press release by ARUP laboratories issued today at <http://www.aruplab.com/AboutARUP/PressRoom/index.jsp>

Further, Epigenomics also will issue a press release on the launch of ARUP's Septin9 test for on Wednesday, July, 21, 2010, 8 am CET. The release can then be found on Epigenomics website under: [http://www.epigenomics.com/en/Newsroom/Press\\_Releases/](http://www.epigenomics.com/en/Newsroom/Press_Releases/)

Epigenomics legal disclaimer. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States. The analytical and clinical performance characteristics of any product based on this technology which may be sold by Epigenomics at some future time in the U.S. have not been established.

end of announcement

euro adhoc

Further inquiry note:

Epigenomics AG  
Dr. Achim Plum  
Sen. VP Corporate Development  
Tel: +49 30 24345 368  
[achim.plum@epigenomics.com](mailto:achim.plum@epigenomics.com)

Branche: Biotechnology  
ISIN: DE000A0BVT96  
WKN: A0BVT9  
Index: Prime All Share, Technology All Share  
Börsen: Frankfurt / regulated dealing/prime standard  
Berlin / free trade  
Hamburg / free trade  
Stuttgart / free trade  
Düsseldorf / free trade  
München / free trade

Original text: Epigenomics AG  
ISIN: DE000A0BVT96  
Digitale Pressemappe: <http://www.presseportal.de/pm/38683/>  
Pressemappe via RSS: [http://presseportal.de/rss/pm\\_38683.rss2](http://presseportal.de/rss/pm_38683.rss2)